Lundstig Annika, Eliasson Linda, Lehtinen Matti, Sasnauskas Kestutis, Koskela Pentti, Dillner Joakim
Department of Medical Microbiology, Malmö University Hospital, Entrance 78, 20502 Malmö, Sweden.
Department of Infectious Disease Epidemiology, National Public Health Institute, Mannerheimintie 166, FIN-00300 Helsinki, Finland.
J Gen Virol. 2005 Jun;86(Pt 6):1703-1708. doi: 10.1099/vir.0.80783-0.
Possible human infection with simian virus 40 (SV40) has been of great concern ever since SV40 was discovered in polio vaccines. Human populations are SV40-seropositive, but because of serological cross-reactivity between SV40 and the human polyomaviruses BK virus (BKV) and JC virus (JCV), it is debatable whether these antibodies are specific. An SV40-specific serological assay was established, based on purified virus-like particles (VLPs), where the SV40 VLPs were blocked with hyperimmune sera to BKV and JCV. Competition with SV40 hyperimmune sera was used as a confirmatory test. Among 288 Swedish children of between 1 and 13 years of age, 7.6 % had SV40-specific antibodies. SV40 seroprevalence reached a peak of 14 % at 7-9 years of age. Among 100 control patients with benign tumours, 9 % were SV40-seropositive. However, SV40 DNA was not detectable in corresponding buffy-coat samples. In serial samples taken up to 5 years apart from 141 Finnish women participating in the population-based serological screening for congenital infections, only two of 141 women were SV40-seropositive in both samples. Six women seroconverted and eight women had a loss of antibodies over time. None of the SV40-seropositive samples contained detectable SV40 DNA. In conclusion, there is a low prevalence of SV40-specific antibodies in the Nordic population. The SV40 antibodies appear to have a low stability over time and their origin is not clear.
自从在脊髓灰质炎疫苗中发现猴病毒40（SV40）以来，人类可能感染该病毒一直备受关注。人群中存在SV40血清阳性情况，但由于SV40与人类多瘤病毒BK病毒（BKV）和JC病毒（JCV）之间存在血清学交叉反应，这些抗体是否具有特异性仍存在争议。基于纯化的病毒样颗粒（VLP）建立了一种SV40特异性血清学检测方法，其中用针对BKV和JCV的超免疫血清阻断SV40 VLP。与SV40超免疫血清的竞争用作确证试验。在288名1至13岁的瑞典儿童中，7.6%拥有SV40特异性抗体。SV40血清阳性率在7至9岁时达到峰值14%。在100名患有良性肿瘤的对照患者中，9%为SV40血清阳性。然而，在相应的血沉棕黄层样本中未检测到SV40 DNA。在对141名参与先天性感染人群血清学筛查的芬兰女性相隔长达5年采集的系列样本中，141名女性中只有2名在两个样本中均为SV40血清阳性。6名女性发生血清转化，8名女性随着时间推移抗体消失。所有SV40血清阳性样本均未检测到可检测的SV40 DNA。总之，北欧人群中SV40特异性抗体的患病率较低。SV40抗体似乎随着时间推移稳定性较低，其来源尚不清楚。
